The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
News|Videos|June 26, 2025
APPULSE-PNH: Oral Iptacopan Monotherapy Demonstrates Clinically Meaningful Hemoglobin (Hb) Increases in Patients (Pts) With Paroxysmal Nocturnal Hemoglobinuria (Pnh) and Hb ≥10 G/Dl Oo Anti-C5 Therapy
Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, presents results from the phase 3b APPULSE-PNH trial at the 2025 EHA Congress in Milan, Italy. The data demonstrate that, in patients with PNH and hemoglobin ≥10 g/dL who switched from anti-C5 therapy to iptacopan, iptacopan was superior in improving hemoglobin levels from baseline.
Advertisement
Advertisement
Related to this article
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring
5